Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Fennec Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Fennec Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $216.00K, down 37.9% year over year. For fiscal 2025 it was $250.00K, down 18.6% from the year before. Over ten years it grew -0.2% a year on average. The highest annual figure on record is $5.61M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.00K | -18.6% |
| FY2024 | Dec 31, 2024 | $307.00K | +448.2% |
| FY2023 | Dec 31, 2023 | $56.00K | -98.4% |
| FY2022 | Dec 31, 2022 | $3.53M | -29.1% |
| FY2021 | Dec 31, 2021 | $4.98M | -2.4% |
| FY2020 | Dec 31, 2020 | $5.11M | -9.0% |
| FY2019 | Dec 31, 2019 | $5.61M | +12.0% |
| FY2018 | Dec 31, 2018 | $5.01M | +158.7% |
| FY2017 | Dec 31, 2017 | $1.94M | +310.2% |
| FY2016 | Dec 31, 2016 | $472.00K | +84.4% |
| FY2015 | Dec 31, 2015 | $256.00K | -28.3% |
| FY2014 | Dec 31, 2014 | $357.00K | -40.2% |
| FY2013 | Dec 31, 2013 | $597.00K | -71.2% |
| FY2012 | Dec 31, 2012 | $2.08M | +38.9% |
| FY2011 | Dec 31, 2011 | $1.49M | +111.0% |
| FY2010 | Dec 31, 2010 | $708.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $118.00K | +10.3% |
| Q1 FY2026 | Mar 31, 2026 | $49.00K | -47.9% |
| Q4 FY2025 | Dec 31, 2025 | $20.00K | -60.0% |
| Q3 FY2025 | Sep 30, 2025 | $29.00K | -70.1% |
| Q2 FY2025 | Jun 30, 2025 | $107.00K | -31.8% |
| Q1 FY2025 | Mar 31, 2025 | $94.00K | +3033.3% |
| Q4 FY2024 | Dec 31, 2024 | $50.00K | +56.3% |
| Q3 FY2024 | Sep 30, 2024 | $97.00K | +708.3% |
| Q2 FY2024 | Jun 30, 2024 | $157.00K | +1862.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.00K | -25.0% |
| Q4 FY2023 | Dec 31, 2023 | $32.00K | -72.6% |
| Q3 FY2023 | Sep 30, 2023 | $12.00K | -98.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.00K | -99.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.00K | -99.7% |
| Q4 FY2022 | Dec 31, 2022 | $117.00K | -77.6% |
| Q3 FY2022 | Sep 30, 2022 | $846.00K | -31.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.13M | +41.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.44M | -40.5% |
| Q4 FY2021 | Dec 31, 2021 | $523.00K | -57.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.24M | -9.2% |
| Q2 FY2021 | Jun 30, 2021 | $800.00K | -28.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.42M | +73.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.22M | +4.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.37M | +72.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.12M | -43.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.39M | -16.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.17M | -32.0% |
| Q3 FY2019 | Sep 30, 2019 | $795.00K | -55.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.97M | +146.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.67M | +142.5% |
| Q4 FY2018 | Dec 31, 2018 | $1.72M | +94.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.80M | +265.4% |
| Q2 FY2018 | Jun 30, 2018 | $798.00K | +139.6% |
| Q1 FY2018 | Mar 31, 2018 | $689.00K | +206.2% |
| Q4 FY2017 | Dec 31, 2017 | $886.00K | +409.2% |
| Q3 FY2017 | Sep 30, 2017 | $492.00K | +339.3% |
| Q2 FY2017 | Jun 30, 2017 | $333.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $225.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $174.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $112.00K | – |
See a number that looks wrong?